If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Melanoma Medicine & Life Sciences
Dacarbazine Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Safety Medicine & Life Sciences
Survival Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1995 2019

  • 8730 Citations
  • 28 h-Index
  • 79 Article
  • 5 Review article
  • 1 Comment/debate
  • 1 Short survey

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 othersRutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 1 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 othersRutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma

Mennini, F. S., Bini, C., Marcellusi, A. & Del Vecchio, M., Oct 2018, In : Clinical Drug Investigation. 38, 10, p. 967-976 10 p.

Research output: Contribution to journalReview article

Melanoma
Costs and Cost Analysis
Therapeutics
Investigational Therapies
Cost of Illness

Cutaneous melanoma in adolescents and young adults

Indini, A., Brecht, I., Del Vecchio, M., Sultan, I., Signoroni, S. & Ferrari, A., Nov 2018, In : Pediatric Blood and Cancer. 65, 11, p. e27292

Research output: Contribution to journalReview article

Young Adult
Melanoma
Skin
Therapeutics
Age Groups

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting

De Santis, F., Del Vecchio, M., Castagnoli, L., De Braud, F., Di Cosimo, S., Franceschini, D., Fucà, G., Hiscott, J., Malmberg, K. J., McGranahan, N., Pietrantonio, F., Rivoltini, L., Sangaletti, S., Tagliabue, E., Tripodo, C., Vernieri, C., Zitvogel, L., Pupa, S. M. & Di Nicola, M., Dec 2018, In : Cytokine and Growth Factor Reviews. 44, p. 1-10 10 p.

Research output: Contribution to journalArticle

Investigational Therapies
Tumors
Monoclonal Antibodies
Neoplasms
Cells